|

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

RECRUITINGPhase 2/3Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Actively Recruiting
PhasePhase 2/3
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
Started2022-12-20
Est. completion2028-12-20
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05749289

Summary

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with suspected or clearly diagnosed SSTR positive tumors
* signed written consent.
* Willing and able to cooperate with all projects in this study.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions3

CancerNeuroendocrine TumorSSTR Positive Tumors

Interventions1

Al18F-octreotide

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.